Literature DB >> 33442029

Treatment and adherence to antihypertensive therapy in France: the roles of socioeconomic factors and primary care medicine in the ESTEBAN survey.

Alexandre Vallée1, Clémence Grave2, Amélie Gabet2, Jacques Blacher3, Valérie Olié2.   

Abstract

Antihypertensive drugs remain one of the main beneficial strategies for cardiovascular disease prevention. The objective of our study was to investigate the associations of different clinical and socioeconomic (SES) factors, and the use of primary care medicine with treatment and adherence (proportion of days covered (PDC) by treatment) to hypertension management in French participants aware of their hypertension. Cross-sectional analyses of treatment for hypertension and adherence to treatment were performed using data from 396 participants from the ESTEBAN survey, a representative sample of the French population. Logistic regression analyses were performed to investigate associations between SES factors (age, sex, education, income, civil status), clinical factors, health care (general practitioner (GP) visits, cardiologist visits, number of consultations, home blood pressure measurement (HBPM)), treatment and adherence. A total of 265 of the 396 hypertensive patients were treated. Antihypertensive drug use was more common among elderly individuals (OR: 2.73 [1.14; 4.32), diabetic patients (OR: 4.18 [1.92; 6.44] and overweight hypertensive patients (OR = 3.04 [1.09; 4.99]). GP consultations and HBPM were associated with increased treatment (OR: 1.03 [1.01; 1.05]; OR: 1.97 [1.06; 2.61], respectively). The PDC was higher among men (p = 0.045) and couples living together (p = 0.018) but lower among diabetic patients (p = 0.012) and patients visiting a cardiologist (p = 0.008). Education and income levels were not associated with either treatment or the PDC. In France, SES factors seemed to have little impact on treatment and adherence to antihypertensive drug regimens. However, treatment administered by GPs and HBPM may play key roles in hypertension management. Although the PDC was quite low, both the number of GP consultations and HBPM were positively associated with pharmacological treatment.

Entities:  

Keywords:  Adherence; Drug treatment; Hypertension; Primary care medicine; Socioeconomic status

Mesh:

Substances:

Year:  2021        PMID: 33442029     DOI: 10.1038/s41440-020-00603-z

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  31 in total

1.  Disparities in adherence to and persistence with antihypertensive regimens: an exploratory analysis from a community-based provider network.

Authors:  Denis Y Ishisaka; Trevor Jukes; Robert J Romanelli; Ken S Wong; Timothy A Schiro
Journal:  J Am Soc Hypertens       Date:  2012 May-Jun

Review 2.  Measuring, analyzing, and managing drug adherence in resistant hypertension.

Authors:  Michel Burnier; Gregoire Wuerzner; Harry Struijker-Boudier; John Urquhart
Journal:  Hypertension       Date:  2013-06-10       Impact factor: 10.190

3.  Global burden of cardiovascular disease.

Authors:  Gregory B Lim
Journal:  Nat Rev Cardiol       Date:  2013-01-08       Impact factor: 32.419

4.  The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months.

Authors:  Björn Wettermark; Niklas Hammar; Carl Michael Fored; C MichaelFored; Andrejs Leimanis; Petra Otterblad Olausson; Ulf Bergman; Ingemar Persson; Anders Sundström; Barbro Westerholm; Måns Rosén
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-07       Impact factor: 2.890

5.  Effect of patient comorbidities on filling of antihypertensive prescriptions.

Authors:  Tara Lagu; Mark G Weiner; Susan Eachus; Simon S K Tang; J Sanford Schwartz; Barbara J Turner
Journal:  Am J Manag Care       Date:  2009-01       Impact factor: 2.229

6.  Hypertension treatment and control in five European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

7.  Measuring concurrent adherence to multiple related medications.

Authors:  Niteesh K Choudhry; William H Shrank; Raisa L Levin; Joy L Lee; Saira A Jan; M Alan Brookhart; Daniel H Solomon
Journal:  Am J Manag Care       Date:  2009-07       Impact factor: 2.229

8.  2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis Clement; Antonio Coca; Giovanni De Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland Schmieder; Evgeny Shlyakhto; Konstantinos Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  J Hypertens       Date:  2018-12       Impact factor: 4.844

9.  Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications?

Authors:  Khedidja Hedna; Katja M Hakkarainen; Hanna Gyllensten; Anna K Jönsson; Karolina Andersson Sundell; Max Petzold; Staffan Hägg
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

Review 10.  Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.

Authors:  T Ninomiya; V Perkovic; F Turnbull; B Neal; F Barzi; A Cass; C Baigent; J Chalmers; N Li; M Woodward; S MacMahon
Journal:  BMJ       Date:  2013-10-03
View more
  1 in total

Review 1.  Social determinants of hypertension in high-income countries: A narrative literature review and future directions.

Authors:  Atsushi Nakagomi; Yuichi Yasufuku; Takayuki Ueno; Katsunori Kondo
Journal:  Hypertens Res       Date:  2022-07-20       Impact factor: 5.528

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.